Please join us on May 30th at 1:00 PM ET for LifeSci’s virtual webinar series “Lunch with LifeSci” featuring Ambrx Inc. (NASDAQ: AMAM) a clinical stage biotechnology company targeting breast and prostate cancer.

Our “Lunch with LifeSci” series highlights promising healthcare investment opportunities by simplifying the complex and making them accessible and understandable to generalist investors who appreciate the alpha it can generate in their investment portfolios.

Ambrx is a next generation Antibody Drug Conjugate (ADC) biotech company targeting breast (ARX788) and prostate cancer (ARX517) with superior conjugation technology in its ADC candidates. The excitement surrounding the ADC drug class is demonstrated by Pfizer’s $43 billion pending 2023 buyout of Seagen, Gilead’s $21 billion buyout of Immunomedics in 2021, and Daiichi Sankyo’s recent Enhertu ADC collaboration with Astra Zeneca.

Ambrx’s ADC platform technology incorporates the advantages of highly specific targeting monoclonal antibodies (mAbs) securely linked to a highly potent chemo cancer killing payload to achieve targeted and efficient elimination of cancer cells. ARX517 (PSMA ADC) is expected to read out preliminary Phase 1 results in Late-Stage Prostate Cancer at a major medical meeting in Q4:23, and the company is also anticipating additional Phase 2 breast cancer data from ARX788 (HER2 ADC) in Q4:23. Please register below to learn more about this potentially game-changing cancer investment opportunity.